TVRD: Tvardi Therapeutics, Inc. - Summary | Jitta

Tvardi Therapeutics, Inc.

NASDAQ:TVRD

Price
$3.57
Loss Chance
59.1%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (10)
Recent Business Performance (33)
Financial Strength (24)
Return to Shareholders (0)
Competitive Advantage (6)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
3.06
97.62%
3.05
206.56%
Pharmaceuticals
4.95
53.41%
5.05
79.98%
5.69
90.19%
COMPANY DESCRIPTION
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.